Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
Cohort Study of Chinese Patients With Pulmonary Vasculitis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Presentation of patient with suspected vasculitis
- Established diagnosis Clinical findings Laboratory workup Tissue biopsy Angiogram where appropriate
- Evaluating respiratory system Chest HRCT Pulmonary function test Bronchoscopy exam(BALF, TBB) Lung biopsy(needle biopsy, VAST)
- screening underlying damage to other system Paranasal sinus, vision & audition Nervous system Kidney Gastrointestinal tract Heart & vessel Skin Hematology Muscle, bone & joint
- Treatment
- Prognosis
Evaluation
- Study visits occurred at baseline; at weeks 4; and at 2, 4, 6,12,18,24,30 months.
- Disease activity was measured on the basis of the BVAS/WG and the physician's global assessment.
- Damage related to disease or treatment was scored according to the Vasculitis Damage Index (scores for this index range from 0 to 64, with higher scores in- dicating more severe damage).
- Health related quality of life was scored with the use of the Med- ical Outcomes Study 36-Item Short-Form Health Survey (SF-36).Scores on this scale range from 0 to 100, with higher scores indicating better health.
- Serial serum samples were tested for proteinase 3-ANCA and myeloperoxidase-ANCA by means of a direct enzyme-linked immunosorbent assay (ELISA).
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Juhong Shi, M.D
- Phone Number: +861069155028
- Email: juhong_shi@hotmail.com
Study Contact Backup
- Name: Ling Qin, M.D
- Phone Number: +861069155028
- Email: qinlingpumch@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and Females
- Aged from 18-75 years with informed consent
Patients with ANCA-vasculitis
- Wegener's granulomatosis, microscopic polyangiitis or CSS
- positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA
- manifestations of activity disease, and Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)
Exclusion Criteria:
- Females planning to bear a child recently or with childbearing potential
- Secondary vasculitis, cancer,infective disease or drug induced vasculitis
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Adults who diagosed ANCA-vasculitis
Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completely Remission
Time Frame: 6 months
|
BVAS/WG of 0 and successful completion of the prednisone taper at 6 months.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease flare
Time Frame: during the period of observation(30months)
|
Disease flare
|
during the period of observation(30months)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: during the period of observation (30months)
|
|
during the period of observation (30months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Juhong Shi, M.D, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Cerebral Small Vessel Diseases
- Vasculitis
- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Systemic Vasculitis
Other Study ID Numbers
Other Study ID Numbers
- PUMCH-PULMONARY DISEASES
- 2011BA11B17 (Other Grant/Funding Number: 2011BA11B17the Ministry of Science and Technology of China)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.